Compile Data Set for Download or QSAR
Report error Found 125 Enz. Inhib. hit(s) with all data for entry = 8870
TargetMu-type opioid receptor(Human)
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM148977(US8962646, A | US10512644, Compound Morphine)
Affinity DataKi:  8.44nMAssay Description:Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/24/2020
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM50105085(US9233167, Nalbuphine | 17-cyclobutylmethyl-4,5alp...)
Affinity DataKi:  14.3nMAssay Description:Briefly, the receptor binding affinity of the nalbuphine and PEG-nalbuphine conjugates was measured using radioligand binding assays in CHO cells tha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/24/2020
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425895(US10512644, Compound alpha-6-mPEG1-O-Morphine)
Affinity DataKi:  15.7nMAssay Description:Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/24/2020
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425934(US10512644, Compound 6-O-mPEG4-Nalbuphine)
Affinity DataKi:  17.5nMAssay Description:Briefly, the receptor binding affinity of the nalbuphine and PEG-nalbuphine conjugates was measured using radioligand binding assays in CHO cells tha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/24/2020
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425896(US10512644, Compound alpha-6-mPEG2-O-Morphine)
Affinity DataKi:  22nMAssay Description:Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/24/2020
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425898(US10512644, Compound alpha-6-mPEG4-O-Morphine)
Affinity DataKi:  23.1nMAssay Description:Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/24/2020
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM50105085(US9233167, Nalbuphine | 17-cyclobutylmethyl-4,5alp...)
Affinity DataKi:  25.9nMAssay Description:Briefly, the receptor binding affinity of the nalbuphine and PEG-nalbuphine conjugates was measured using radioligand binding assays in CHO cells tha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/24/2020
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425933(US10512644, Compound 6-O-mPEG3-Nalbuphine)
Affinity DataKi:  27.4nMAssay Description:Briefly, the receptor binding affinity of the nalbuphine and PEG-nalbuphine conjugates was measured using radioligand binding assays in CHO cells tha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/24/2020
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM148977(US8962646, A | US10512644, Compound Morphine)
Affinity DataEC50:  28.5nMAssay Description:Briefly, suspensions of cells expressing either the mu, kappa or delta opioid receptors were prepared in buffer containing 0.5 mM isobutyl-methyl xan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/24/2020
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425935(US10512644, Compound 6-O-mPEG5-Nalbuphine)
Affinity DataKi:  35.1nMAssay Description:Briefly, the receptor binding affinity of the nalbuphine and PEG-nalbuphine conjugates was measured using radioligand binding assays in CHO cells tha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/24/2020
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425935(US10512644, Compound 6-O-mPEG5-Nalbuphine)
Affinity DataKi:  35.6nMAssay Description:Briefly, the receptor binding affinity of the nalbuphine and PEG-nalbuphine conjugates was measured using radioligand binding assays in CHO cells tha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/24/2020
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425899(US10512644, Compound alpha-6-mPEG5-O-Morphine)
Affinity DataKi:  39.4nMAssay Description:Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/24/2020
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425936(US10512644, Compound 6-O-mPEG6-Nalbuphine)
Affinity DataKi:  44.3nMAssay Description:Briefly, the receptor binding affinity of the nalbuphine and PEG-nalbuphine conjugates was measured using radioligand binding assays in CHO cells tha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/24/2020
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425897(US10512644, Compound alpha-6-mPEG3-O-Morphine)
Affinity DataKi:  50.7nMAssay Description:Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/24/2020
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425901(US10512644, Compound alpha-6-mPEG7-O-Morphine)
Affinity DataKi:  56.9nMAssay Description:Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/24/2020
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425922(US10512644, Compound Hydrocodone)
Affinity DataIC50: 63.7nMAssay Description:Using conventional in vitro mu opioid receptor binding affinity assays, IC50 values were determined for each of alpha-6-mPEGn-O-hydrocodonol compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/24/2020
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425900(US10512644, Compound alpha-6-mPEG6-O-Morphine)
Affinity DataKi:  73nMAssay Description:Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/24/2020
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425937(US10512644, Compound 6-O-mPEG7-Nalbuphine)
Affinity DataKi:  77.9nMAssay Description:Briefly, the receptor binding affinity of the nalbuphine and PEG-nalbuphine conjugates was measured using radioligand binding assays in CHO cells tha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/24/2020
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425938(US10512644, Compound 6-O-mPEG8-Nalbuphine)
Affinity DataKi:  79.5nMAssay Description:Briefly, the receptor binding affinity of the nalbuphine and PEG-nalbuphine conjugates was measured using radioligand binding assays in CHO cells tha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/24/2020
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425895(US10512644, Compound alpha-6-mPEG1-O-Morphine)
Affinity DataEC50:  85nMAssay Description:Briefly, suspensions of cells expressing either the mu, kappa or delta opioid receptors were prepared in buffer containing 0.5 mM isobutyl-methyl xan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/24/2020
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425896(US10512644, Compound alpha-6-mPEG2-O-Morphine)
Affinity DataEC50:  93.3nMAssay Description:Briefly, suspensions of cells expressing either the mu, kappa or delta opioid receptors were prepared in buffer containing 0.5 mM isobutyl-methyl xan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/24/2020
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425902(US10512644, Compound alpha-6-mPEG9-O-Morphine)
Affinity DataKi:  111nMAssay Description:Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/24/2020
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM148977(US8962646, A | US10512644, Compound Morphine)
Affinity DataKi:  118nMAssay Description:Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/24/2020
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425939(US10512644, Compound 6-O-mPEG9-Nalbuphine)
Affinity DataKi:  122nMAssay Description:Briefly, the receptor binding affinity of the nalbuphine and PEG-nalbuphine conjugates was measured using radioligand binding assays in CHO cells tha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/24/2020
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425898(US10512644, Compound alpha-6-mPEG4-O-Morphine)
Affinity DataEC50:  128nMAssay Description:Briefly, suspensions of cells expressing either the mu, kappa or delta opioid receptors were prepared in buffer containing 0.5 mM isobutyl-methyl xan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/24/2020
Entry Details
US Patent

TargetDelta-type opioid receptor(Human)
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425936(US10512644, Compound 6-O-mPEG6-Nalbuphine)
Affinity DataKi:  130nMAssay Description:Briefly, the receptor binding affinity of the nalbuphine and PEG-nalbuphine conjugates was measured using radioligand binding assays in CHO cells tha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/24/2020
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425903(US10512644, Compound Oxycodone)
Affinity DataKi:  133nMAssay Description:Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/24/2020
Entry Details
US Patent

TargetDelta-type opioid receptor(Human)
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425935(US10512644, Compound 6-O-mPEG5-Nalbuphine)
Affinity DataKi:  148nMAssay Description:Briefly, the receptor binding affinity of the nalbuphine and PEG-nalbuphine conjugates was measured using radioligand binding assays in CHO cells tha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/24/2020
Entry Details
US Patent

TargetDelta-type opioid receptor(Human)
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425934(US10512644, Compound 6-O-mPEG4-Nalbuphine)
Affinity DataKi:  149nMAssay Description:Briefly, the receptor binding affinity of the nalbuphine and PEG-nalbuphine conjugates was measured using radioligand binding assays in CHO cells tha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/24/2020
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425899(US10512644, Compound alpha-6-mPEG5-O-Morphine)
Affinity DataEC50:  157nMAssay Description:Briefly, suspensions of cells expressing either the mu, kappa or delta opioid receptors were prepared in buffer containing 0.5 mM isobutyl-methyl xan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/24/2020
Entry Details
US Patent

TargetDelta-type opioid receptor(Human)
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425939(US10512644, Compound 6-O-mPEG9-Nalbuphine)
Affinity DataKi:  158nMAssay Description:Briefly, the receptor binding affinity of the nalbuphine and PEG-nalbuphine conjugates was measured using radioligand binding assays in CHO cells tha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/24/2020
Entry Details
US Patent

TargetDelta-type opioid receptor(Human)
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425933(US10512644, Compound 6-O-mPEG3-Nalbuphine)
Affinity DataKi:  163nMAssay Description:Briefly, the receptor binding affinity of the nalbuphine and PEG-nalbuphine conjugates was measured using radioligand binding assays in CHO cells tha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/24/2020
Entry Details
US Patent

TargetDelta-type opioid receptor(Human)
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425938(US10512644, Compound 6-O-mPEG8-Nalbuphine)
Affinity DataKi:  168nMAssay Description:Briefly, the receptor binding affinity of the nalbuphine and PEG-nalbuphine conjugates was measured using radioligand binding assays in CHO cells tha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/24/2020
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425939(US10512644, Compound 6-O-mPEG9-Nalbuphine)
Affinity DataKi:  186nMAssay Description:Briefly, the receptor binding affinity of the nalbuphine and PEG-nalbuphine conjugates was measured using radioligand binding assays in CHO cells tha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/24/2020
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425933(US10512644, Compound 6-O-mPEG3-Nalbuphine)
Affinity DataKi:  218nMAssay Description:Briefly, the receptor binding affinity of the nalbuphine and PEG-nalbuphine conjugates was measured using radioligand binding assays in CHO cells tha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/24/2020
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425936(US10512644, Compound 6-O-mPEG6-Nalbuphine)
Affinity DataKi:  247nMAssay Description:Briefly, the receptor binding affinity of the nalbuphine and PEG-nalbuphine conjugates was measured using radioligand binding assays in CHO cells tha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/24/2020
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425897(US10512644, Compound alpha-6-mPEG3-O-Morphine)
Affinity DataEC50:  270nMAssay Description:Briefly, suspensions of cells expressing either the mu, kappa or delta opioid receptors were prepared in buffer containing 0.5 mM isobutyl-methyl xan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/24/2020
Entry Details
US Patent

TargetDelta-type opioid receptor(Human)
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425937(US10512644, Compound 6-O-mPEG7-Nalbuphine)
Affinity DataKi:  314nMAssay Description:Briefly, the receptor binding affinity of the nalbuphine and PEG-nalbuphine conjugates was measured using radioligand binding assays in CHO cells tha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/24/2020
Entry Details
US Patent

TargetDelta-type opioid receptor(Human)
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM50105085(US9233167, Nalbuphine | 17-cyclobutylmethyl-4,5alp...)
Affinity DataKi:  319nMAssay Description:Briefly, the receptor binding affinity of the nalbuphine and PEG-nalbuphine conjugates was measured using radioligand binding assays in CHO cells tha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/24/2020
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425937(US10512644, Compound 6-O-mPEG7-Nalbuphine)
Affinity DataKi:  346nMAssay Description:Briefly, the receptor binding affinity of the nalbuphine and PEG-nalbuphine conjugates was measured using radioligand binding assays in CHO cells tha...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/24/2020
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425925(US10512644, Compound alpha-6-mPEG2-O-Hydrocodonol)
Affinity DataIC50: 372nMAssay Description:Using conventional in vitro mu opioid receptor binding affinity assays, IC50 values were determined for each of alpha-6-mPEGn-O-hydrocodonol compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/24/2020
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425926(US10512644, Compound alpha-6-mPEG3-O-Hydrocodonol)
Affinity DataIC50: 374nMAssay Description:Using conventional in vitro mu opioid receptor binding affinity assays, IC50 values were determined for each of alpha-6-mPEGn-O-hydrocodonol compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/24/2020
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425924(US10512644, Compound alpha-6-mPEG1-O-Hydrocodonol)
Affinity DataIC50: 384nMAssay Description:Using conventional in vitro mu opioid receptor binding affinity assays, IC50 values were determined for each of alpha-6-mPEGn-O-hydrocodonol compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/24/2020
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425928(US10512644, Compound alpha-6-mPEG5-O-Hydrocodonol)
Affinity DataIC50: 395nMAssay Description:Using conventional in vitro mu opioid receptor binding affinity assays, IC50 values were determined for each of alpha-6-mPEGn-O-hydrocodonol compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/24/2020
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425896(US10512644, Compound alpha-6-mPEG2-O-Morphine)
Affinity DataKi:  404nMAssay Description:Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/24/2020
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425900(US10512644, Compound alpha-6-mPEG6-O-Morphine)
Affinity DataEC50:  415nMAssay Description:Briefly, suspensions of cells expressing either the mu, kappa or delta opioid receptors were prepared in buffer containing 0.5 mM isobutyl-methyl xan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/24/2020
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425898(US10512644, Compound alpha-6-mPEG4-O-Morphine)
Affinity DataKi:  439nMAssay Description:Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/24/2020
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425895(US10512644, Compound alpha-6-mPEG1-O-Morphine)
Affinity DataKi:  445nMAssay Description:Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/24/2020
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425927(US10512644, Compound alpha-6-mPEG4-O-Hydrocodonol)
Affinity DataIC50: 454nMAssay Description:Using conventional in vitro mu opioid receptor binding affinity assays, IC50 values were determined for each of alpha-6-mPEGn-O-hydrocodonol compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/24/2020
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Inheris Pharmaceuticals

US Patent
LigandPNGBDBM425923(US10512644, Compound alpha-6-Hydrocodonol)
Affinity DataIC50: 478nMAssay Description:Using conventional in vitro mu opioid receptor binding affinity assays, IC50 values were determined for each of alpha-6-mPEGn-O-hydrocodonol compound...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/24/2020
Entry Details
US Patent

Displayed 1 to 50 (of 125 total ) | Next | Last >>
Jump to: